Table 2.
oral candidiasis in the study population
| Presence of oral candidiasis (N=18) | Absence of oral candidiasis (N=145) | p-value | ||
|---|---|---|---|---|
| Gender | Female | 9 (9.0) | 91 (91.0) | 0.29 |
| Male | 9 (14.3) | 54 (85.7) | ||
| Age (Years) | 21-30 | 4 (12.5) | 28 (87.5) | 0.76 |
| 31-40 | 8 (13.1) | 53 (86.9) | ||
| 41-50 | 3 (6.8) | 41(93.2) | ||
| ≥51 | 3 (11.5) | 23 (88.5) | ||
| Oral hygiene | Good | 0 (0.0) | 6 (100.0) | 0.24 |
| Average | 15 (10.4) | 129 (89.6) | ||
| Poor | 3 (23.1) | 10 (76.9) | ||
| CD4 count (cells/mm3) | <200 | 14 (77.8) | 46 (31.7) | p<0.0001 |
| ≥200 | 4 (22.2) | 99 (68.3) | ||
| HIV viral load (copies/ml) | < 1000 | 3 (16.7) | 109 (75.1) | p<0.0001 |
| ≥ 1000 | 15 (83.3) | 36 (24.8) | ||
| Antiretroviral treatment exposure | ART naive | 11 (21.6) | 40 (78.4) | p=0.003 |
| Antiretroviral treatment treated | 7 (6.3) | 105 (93.7) | ||
| Compliance to antiretroviral treatment | Yes | 3 (3.2) | 90 (96.8) | p=0.0034 |
| No | 4(21.0) | 15 (79.0) | ||
| Antiretroviral treatment regimen | Zidovudine + Lamivudine+ Nevirapine | 2 (20.0) | 8 (80.0) | p= 0.1303 |
| Tenofovir (TDF) + lamivudine (3TC) + Efavirenz (EFV) | 5 (6.3) | 74 (93.7) | ||
| Zidovudine+Lamivudine+Nevirapine | 0 (0.0) | 23 (100.0) |